TRPV1 and bone cancer: Also, the intrathecal administration of the TRPA1 antagonist (HC-030031) and non-selective antagonists for TRPV1 (iodoresiniferatoxin) and TRPV4 (gadolinium) downregulated bone-cancer-enhanced IL-17A expression, indicating that TRP channels might promote spinal IL-17A upregulation to facilitate pain.